US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polaryx Therapeutics Inc

2.07

-0.0700-3.27%

Post-market: 2.070.00000.00%19:53 EDT

Volume:108.47K

Turnover:222.69K

Market Cap:103.18M

PE:-15.11

High:2.15

Open:2.14

Low:2.03

Close:2.14

52wk High:48.91

52wk Low:1.86

Shares:49.85M

Float Shares:6.78M

Volume Ratio:0.79

T/O Rate:1.60%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1370

EPS(LYR):-0.1978

ROE:-96.56%

ROA:-42.52%

PB:9.43

PE(LYR):-10.46

Loading ...

Overview Company News Filings

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCI

BUZZ-Polaryx rises after FDA grants fast-track status for rare disease drug

Polaryx receives U.S. FDA Fast Track Designation for PLX-200

Polaryx Therapeutics, Inc - to Initiate Soteria Phase 2 Trial in Second Half of 2026

THOMSON REUTERS

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Polaryx Therapeutics to present at Needham Virtual Healthcare Conference

Polaryx FY2025 net loss narrows 70.4% to USD 9 million

FDA grants Fast Track designation to Polaryx Therapeutics’ PLX-200 for CLN2 disease

Polaryx Therapeutics, Inc - to Initiate Soteria Trial in Q3 2026 Following FDA Safe to Proceed Letter

THOMSON REUTERS

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM

Polaryx Therapeutics to attend Krabbe Translational Research Network meeting and Putt-Putt to #CureKrabbe event

Maxim Group Initiates a Buy Rating on Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics Initiated at Buy by Maxim Group

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

Polaryx initiated with a Buy at Maxim

Polaryx Therapeutics CFO and Director G. Michael Landis Acquires Common Shares

What's Going On With Polaryx Therapeutics Stock Wednesday?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/PLYX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics Inc","latestPrice":2.07,"timestamp":1787342400000,"preClose":2.14,"halted":0,"volume":108472,"hourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"19:53 EDT","volume":64,"amount":132.5006,"timestamp":1787356396629,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.032710280373831904,"floatShares":6777800,"shares":49846000,"eps":-0.137,"marketStatus":"Market Closed","change":-0.07,"latestTime":"08-21 16:00:00 EDT","open":2.14,"high":2.15,"low":2.03,"amount":222692.690584,"amplitude":0.056075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.137,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.01,"preClose":2.14,"latestTime":"09:28 EDT","volume":12117,"amount":24449.735914800003,"timestamp":1787318913067,"change":-0.13,"changeRate":-0.060748,"amplitude":0.11215},"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"19:53 EDT","volume":64,"amount":132.5006,"timestamp":1787356396629,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7916797426893581},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":6777800,"roa":"-42.52%","roe":"-96.56%","lyrEps":-0.197809,"volumeRatio":0.7916797426893581,"shares":49846000,"dividePrice":0,"high":2.15,"amplitude":0.056075,"preClose":2.14,"low":2.03,"week52Low":1.86,"pbRate":"9.43","week52High":48.91,"institutionHeld":0,"latestPrice":2.07,"eps":-0.137,"divideRate":0,"volume":108472,"delay":0,"ttmEps":-0.137,"open":2.14,"prevYearClose":45,"prevWeekClose":2.6,"prevMonthClose":2.31,"prevQuarterClose":2.66,"fiveDayClose":2.6,"twentyDayClose":2.05,"sixtyDayClose":2.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PLYX","fiscalQuarterEnding":"2026/06","expectedEps":-0.05,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1786680000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-08-21","current":-15.109489,"percent":0.913669,"low":-201.755192,"twenty":-31.888849,"median":-18.858377,"eighty":-16.490115,"high":-13.892286,"avg":-26.119255,"sd":21.979805,"marketCap":106670425},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-06","current":-92.230945,"twenty":-129.699766,"median":-109.380137,"eighty":-58.797227,"marketCap":757492752},{"date":"2026-02-13","current":-16.832147,"twenty":-126.529328,"median":-58.797227,"eighty":-25.939953,"marketCap":138242427},{"date":"2026-02-20","current":-15.391039,"twenty":-99.090622,"median":-34.183094,"eighty":-16.79756,"marketCap":126406602},{"date":"2026-02-27","current":-18.388545,"twenty":-65.483971,"median":-21.847205,"eighty":-15.852193,"marketCap":151025117},{"date":"2026-03-06","current":-15.102817,"twenty":-58.797227,"median":-17.581524,"eighty":-15.852193,"marketCap":124039438},{"date":"2026-03-13","current":-26.804618,"twenty":-52.848332,"median":-19.339676,"eighty":-15.932895,"marketCap":220146331},{"date":"2026-03-20","current":-32.569052,"twenty":-39.601662,"median":-22.827159,"eighty":-16.059713,"marketCap":267489628},{"date":"2026-03-27","current":-33.617166,"twenty":-34.863297,"median":-29.312147,"eighty":-16.128886,"marketCap":302050234},{"date":"2026-04-02","current":-40.045527,"twenty":-39.919067,"median":-31.906143,"eighty":-16.140415,"marketCap":359809057},{"date":"2026-04-10","current":-30.350294,"twenty":-38.506935,"median":-31.819676,"eighty":-16.417108,"marketCap":272697390},{"date":"2026-04-17","current":-33.669857,"twenty":-37.045768,"median":-31.906143,"eighty":-16.636156,"marketCap":302523667},{"date":"2026-04-24","current":-28.031869,"twenty":-35.562162,"median":-31.819676,"eighty":-16.762974,"marketCap":251866340},{"date":"2026-05-01","current":-27.663028,"twenty":-34.579831,"median":-30.218565,"eighty":-17.281773,"marketCap":248552309},{"date":"2026-05-08","current":-20.128146,"twenty":-34.275325,"median":-29.928762,"eighty":-18.065737,"marketCap":180851394},{"date":"2026-05-15","current":-17.967795,"twenty":-34.128071,"median":-28.532438,"eighty":-17.67102,"marketCap":161440642},{"date":"2026-05-22","current":-28.799226,"twenty":-34.059774,"median":-27.768411,"eighty":-17.809721,"marketCap":186532590},{"date":"2026-05-29","current":-22.293817,"twenty":-33.996545,"median":-27.504954,"eighty":-17.904565,"marketCap":144397055},{"date":"2026-06-05","current":-18.492904,"twenty":-33.827932,"median":-26.891329,"eighty":-18.119363,"marketCap":119778541},{"date":"2026-06-12","current":-17.396487,"twenty":-33.648781,"median":-26.314014,"eighty":-17.641188,"marketCap":112677046},{"date":"2026-06-18","current":-16.884826,"twenty":-33.534361,"median":-25.713443,"eighty":-17.290923,"marketCap":109363016},{"date":"2026-06-26","current":-16.884826,"twenty":-33.180562,"median":-24.313934,"eighty":-17.139848,"marketCap":109363016},{"date":"2026-07-02","current":-18.858377,"twenty":-33.090251,"median":-23.364528,"eighty":-17.282806,"marketCap":122145706},{"date":"2026-07-10","current":-17.761959,"twenty":-32.741985,"median":-22.293817,"eighty":-17.323392,"marketCap":115044211},{"date":"2026-07-17","current":-16.884826,"twenty":-32.569052,"median":-20.503003,"eighty":-17.031015,"marketCap":109363016},{"date":"2026-07-24","current":-15.422936,"twenty":-32.510645,"median":-20.174077,"eighty":-16.884826,"marketCap":99894356},{"date":"2026-07-31","current":-15.715314,"twenty":-32.46514,"median":-20.022763,"eighty":-16.813445,"marketCap":101788088},{"date":"2026-08-07","current":-16.226975,"twenty":-32.288502,"median":-19.406585,"eighty":-16.664276,"marketCap":105102119},{"date":"2026-08-14","current":-18.273621,"twenty":-31.997409,"median":-19.285083,"eighty":-16.519353,"marketCap":118358242},{"date":"2026-08-21","current":-15.574598,"twenty":-31.888849,"median":-18.858377,"eighty":-16.490115,"marketCap":106670425}],"updateTime":1787461618351},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLYX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635574894","title":"Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2635574894","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635574894?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:15","pubTimestamp":1778764500,"startTime":"0","endTime":"0","summary":"Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award WinnerPARAMUS, NJ, May  14, 2026  (GLOBE NEWSWIRE) -- Pol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295060/0/en/Polaryx-Therapeutics-Receives-GHP-Magazine-s-Healthcare-Pharmaceuticals-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PLYX","BK4581","XLV","HCSG","LU0128526141.USD","LU0029874061.USD","BK4585","BK4007","BK4137","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629496831","title":"Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2629496831","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629496831?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:30","pubTimestamp":1776947400,"startTime":"0","endTime":"0","summary":"PARAMUS, NJ, April  23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysos","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3279922/0/en/Polaryx-Therapeutics-to-Participate-in-National-Tay-Sachs-Allied-Diseases-Association-Annual-Family-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX","NHLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629605562","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCI","url":"https://stock-news.laohu8.com/highlight/detail?id=2629605562","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629605562?lang=en_us&edition=fundamental","pubTime":"2026-04-21 23:49","pubTimestamp":1776786546,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCIWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nL6N414143:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TER","INTW","RDTL","DGX","MSCI","RTX","HLXX","ELV","SHW","TSCO","CE","GE","MMM","NTRS","CRML","AMZU","CDE","CNC","AXTI","ALK","HAL","AAPL","CVS","MACW.SI","HL","AAPX","HUM","AAPU","APD","SPRB","AAPB","DHI","AMZN","AMZD","PBI","ECL","INTC","RDDT","ALAB","UNH","TERG","FRMI","MRVL","PLYX","AAPD","CRMX","DHR","AMZP","MVLL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629034752","title":"BUZZ-Polaryx rises after FDA grants fast-track status for rare disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2629034752","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629034752?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:11","pubTimestamp":1776777102,"startTime":"0","endTime":"0","summary":"BUZZ-Polaryx rises after FDA grants fast-track status for rare disease drug** Shares of drug developer Polaryx Therapeutics PLYX.O rise 4.76% to $5.97 premarket** Company says the U.S. FDA has granted fast-track status to its experimental drug, PLX-200, for CLN3 disease, Krabbe disease and Sandhoff disease — three rare genetic disorders that damage the nervous system** FDA's fast-track tag is meant to speed up development and review of treatments for serious diseases with unmet medical needs** With the fast-track grant it received in March for CLN2 disease, PLX-200 now has the designation for all four disorders planned for its next study - PLYX** Company plans to start a mid-stage study in the second half of 2026, testing PLX-200 across all four disorders in the United States, Europe and Asia** PLYX shares down 83.7% since their IPO in February  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nL4N41419E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603469","title":"Polaryx receives U.S. FDA Fast Track Designation for PLX-200","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603469?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:59","pubTimestamp":1776776395,"startTime":"0","endTime":"0","summary":"Polaryx (PLYX) Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to PLX-200 for the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-receives-u-s-fda-fast-track-designation-for-plx-200-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-receives-u-s-fda-fast-track-designation-for-plx-200-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLYX","BK4007","LABU","BK4588","BK4585","BK4139","PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629392740","title":"Polaryx Therapeutics, Inc - to Initiate Soteria Phase 2 Trial in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629392740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629392740?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:30","pubTimestamp":1776774601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUABY5R7Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629039015","title":"Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629039015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629039015?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:30","pubTimestamp":1776774600,"startTime":"0","endTime":"0","summary":"PARAMUS, N.J., April  21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, tod","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3277945/0/en/Polaryx-Therapeutics-Receives-U-S-FDA-Fast-Track-Designations-for-All-Four-Indications-to-be-Evaluated-in-the-SOTERIA-Basket-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBB","LABU","BK4007","BK4588","PLYX","BK4585","HSCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627280357","title":"Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2627280357","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627280357?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:15","pubTimestamp":1776258900,"startTime":"0","endTime":"0","summary":"Company selected as a Diamond honoree for Excellence in Pediatric CarePARAMUS, NJ, April  15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focus","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274544/0/en/Polaryx-Therapeutics-Recognized-with-Pinnacle-Award-for-Excellence-in-Pediatric-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515627","title":"Polaryx Therapeutics to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515627","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515627?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:31","pubTimestamp":1775046700,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics will take part in Needham Virtual Healthcare Conference April 13-16, 2026.Group presentation set for April 16, 2026 at 10:15 a.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1xrQbf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BKPKM429.USD","BK4112","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","BK4007","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","PLYX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621916063","title":"Polaryx FY2025 net loss narrows 70.4% to USD 9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621916063","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621916063?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:01","pubTimestamp":1774346515,"startTime":"0","endTime":"0","summary":"Polaryx published its annual report  reporting a net loss and comprehensive loss of USD 9.0 million and an operating loss of USD 7.8 million.Research and development expenses rose more than doubled to USD 6.3 million, driven mainly by consulting costs, work under the Rush MSA, CRO services, and stock-based compensation tied to shares issued for an exclusive gene therapy patent license.General and administrative expenses were USD 1.6 million.Cash and cash equivalents were USD 5.1 million, and Polaryx said this is expected to fund operations through the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL9zbyzp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620422344","title":"FDA grants Fast Track designation to Polaryx Therapeutics’ PLX-200 for CLN2 disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422344","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422344?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:33","pubTimestamp":1773750819,"startTime":"0","endTime":"0","summary":"The FDA granted Fast Track designation to Polaryx’s PLX-200 for the treatment of late-infantile neuronal ceroid lipofuscinosis . Polaryx said the designation supports advancement of its Phase 2 SOTERIA basket trial evaluating PLX-200 across CLN2, CLN3, Krabbe disease, and Sandhoff disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL95zvkc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4588","SG9999014039.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","PLYX","SG9999014021.USD","SG9999014013.SGD","BK4007","NDAQ","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424065","title":"Polaryx Therapeutics, Inc - to Initiate Soteria Trial in Q3 2026 Following FDA Safe to Proceed Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424065?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA3FLQYS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618130726","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:02 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130726","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130726?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:02","pubTimestamp":1773327736,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:02 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nAQN2LPYTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618613289","title":"Polaryx Therapeutics to attend Krabbe Translational Research Network meeting and Putt-Putt to #CureKrabbe event","url":"https://stock-news.laohu8.com/highlight/detail?id=2618613289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618613289?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:33","pubTimestamp":1773318794,"startTime":"0","endTime":"0","summary":"Polaryx will attend the 2026 Krabbe Translational Research Network meeting on March 18-20, 2026 in Minneapolis, Minnesota. Polaryx will also attend the 2026 Putt-Putt to #CureKrabbe event on March 20, 2026 in Edina, Minnesota.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL4s3ZPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2095319765.USD","SG9999014039.USD","LU2210149790.SGD","BK4588","LU2210150020.SGD","BK4007","BK4585","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616385368","title":"Maxim Group Initiates a Buy Rating on Polaryx Therapeutics, Inc. (PLYX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616385368","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616385368?lang=en_us&edition=fundamental","pubTime":"2026-03-03 02:36","pubTimestamp":1772476584,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Polaryx Therapeutics, Inc. on February 27 and set a price target of $10....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-initiates-a-buy-rating-on-polaryx-therapeutics-inc-plyx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-initiates-a-buy-rating-on-polaryx-therapeutics-inc-plyx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614674598","title":"Polaryx Therapeutics Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2614674598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614674598?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:38","pubTimestamp":1772228280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PLYX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 16:38 ET (21:38 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614919859","title":"Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2614919859","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614919859?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:30","pubTimestamp":1772199000,"startTime":"0","endTime":"0","summary":"PARAMUS, NJ, Feb.  27, 2026  (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246511/0/en/Polaryx-Therapeutics-Marks-Rare-Disease-Day-Reaffirming-Commitment-to-Patients-with-Rare-Pediatric-Lysosomal-Storage-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NORD","PLYX","BK4127","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614856193","title":"Polaryx initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614856193?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:15","pubTimestamp":1772198101,"startTime":"0","endTime":"0","summary":"Maxim initiated coverage of Polaryx (PLYX) with a Buy rating and $10 price target Published first on TheFly – the ultimate source for real-time, ma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613290390","title":"Polaryx Therapeutics CFO and Director G. Michael Landis Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613290390","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613290390?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:42","pubTimestamp":1771623741,"startTime":"0","endTime":"0","summary":"Landis G. Michael, Chief Financial Officer and a director of Polaryx Therapeutics, Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL1XDFzW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Polaryx Therapeutics CFO and Director G. Michael Landis Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612813442","title":"What's Going On With Polaryx Therapeutics Stock Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2612813442","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612813442?lang=en_us&edition=fundamental","pubTime":"2026-02-18 23:19","pubTimestamp":1771427940,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics Inc.  stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday.The stock closed Tuesday up 64.32% at $3.96, after the company announced it had selected a contract research organization  for its SOTERIA Phase 2 basket trial.The trial is designed to evaluate PLX-200, Polaryx’s lead candidate, across multiple lysosomal storage disorders.Polaryx said the CRO selection marks a pivotal milestone as it prepares to initiate the trial in the first half of 2026. The trial will assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders.Polaryx previously received a safe-to-proceed letter from the FDA in October 2025. The SOTERIA trial will incorporate natural history data as a control arm compared to the PLX-200 treated arm.PLX-200 is an orally available compound derived from gemfibrozil. The company noted that compelling clinical activity cou","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/18/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/18/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50689541/whats-going-on-with-polaryx-therapeutics-stock-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50689541/whats-going-on-with-polaryx-therapeutics-stock-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}